Apogee Therapeutics

Subsidiary of AbbVie (ABBV)

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
IL-13Monoclonal antibody
Atopic DermatitisAsthma
Phase 1
IL-4R-alphaMonoclonal antibody
Chronic Obstructive Pulmonary Disease
Phase 1
OX40LMonoclonal antibody
Atopic Dermatitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
ZumilokibartPhase 2Atopic Dermatitis
Est. primary completion 2026-11 · NCT06395948 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
ZumilokibartPhase 2Atopic Dermatitis
Est. primary completion 2029-12 · NCT07003425 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026Topline resultZumilokibartPhase 2 APEX Part B primary results
27 May 2026Topline resultZumilokibartPositive 16-week APEX Part B Phase 2 topline results for zumilokibart
7 July 2025Topline resultZumilokibartAPEX Phase 2 Part A (APG777) met its primary endpoint at Week 16
Apogee Therapeutics · Source ↗
12 May 2025Topline resultAPG808APG808 Phase 1b interim results in asthma

Financial reports

Quarterly & interim (13)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$67M$106M+ $866M short-term inv.$86M-$71M operating cash flowreport ↗
View 12 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0—$1.3B—report ↗
2025-Q3—$54M$108M+ $419M short-term inv.$65M-$54M operating cash flowreport ↗
2025-Q2—$56M$124M+ $381M short-term inv.$66M-$62M operating cash flowreport ↗
2025-Q1—$46M$107M+ $406M short-term inv.$55M-$48M operating cash flowreport ↗
2024-Q3—$46M$119M+ $407M short-term inv.$49M-$43M operating cash flowreport ↗
2024-Q2—$33M$308M+ $369M short-term inv.$34M-$29M operating cash flowreport ↗
2024-Q1—$29M$486M+ $331M short-term inv.$32M-$32M operating cash flowreport ↗
2023-Q3—$17M$188M+ $235M short-term inv.$21M-$20M operating cash flowreport ↗
2023-Q2—$14M$125M$19M-$15M operating cash flowreport ↗
2023-Q1—$8.5M$141M$13M-$11M operating cash flowreport ↗
2022-Q3—$9.9M$2.6M$20Mreport ↗
2022-Q2—$1.4M$5.0M$1.8Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$215M$132M+ $599M short-term inv.$64M-$227M operating cash flowreport ↗

Apogee Therapeutics reported no revenue for fiscal year 2025, with R&D spend of $214.71M, up 27.9% YoY. Cash and equivalents were $131.55M, and the company reported a net loss of $255.84M.

The 10-K details clinical progress across its pipeline, including positive 16-week APEX Part A data for zumilokibart in atopic dermatitis, ahead-of-schedule completion of Part B enrollment with 347 patients, and expected 16-week Part B topline data in Q2 2026 with a potential Phase 3 initiation in the second half of 2026. Positive interim results were also reported for the APG808 Phase 1b asthma trial, the APG333 Phase 1 trial, and the zumilokibart Phase 1b asthma trial. The APG279 Phase 1b trial against DUPIXENT is ongoing with a readout expected in the second half of 2026.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$168M$142M+ $379M short-term inv.$46M-$171M operating cash flowreport ↗
2023-FY—$68M$119M+ $277M short-term inv.$21M-$75M operating cash flowreport ↗
2022-FY——$152M—report ↗